GlassScriptPhysician profile
Henrik Wilms
NPI 1770850513
$116,648.36
in general payments reported to CMS, 2019-2025
15 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $9,309 · 2021: $14K · 2022: $6,918 · 2023: $39K · 2024: $21K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Consulting Fee: $19K · Travel and Lodging: $6,260 · Food and Beverage: $4,047 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,380.38 |
| Consulting Fee | $19,122.50 |
| Travel and Lodging | $6,259.52 |
| Food and Beverage | $4,047.25 |
| Education | $252.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $79,516.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $35,001.14 | 2019-2025 | Ingrezza |
| Medtronic, INC. | $999.08 | 2024-2025 | Percept PC Brainsense |
| Abbott Laboratories | $301.25 | 2023-2024 | Infinity |
| Genzyme Corporation | $252.43 | 2019-2023 | |
| Insightec,INC | $145.84 | 2025 | Exablate |
| Kyowa Kirin, INC. | $116.24 | 2023 | Nourianz |
| Celgene Corporation | $93.39 | 2019 | |
| Biogen, INC. | $64.37 | 2022-2024 | Tysabri, Vumerity, Tecfidera |
| Emd Serono, INC. | $47.28 | 2019-2025 | |
| Sk Life Science, INC. | $26.72 | 2022 | |
| Lundbeck LLC | $25.59 | 2022 | |
| Eisai INC. | $24.78 | 2024 | |
| Amgen INC. | $18.55 | 2025 | Uplizna |
| Acorda Therapeutics, INC | $15.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henrik Wilms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.